ProCE Banner Activity

FAQs: Importance of Biomarker Testing in NSCLC

Clinical Thought
In this commentary, Drs Matthew Gubens, a thoracic oncologist, and Craig Mackinnon, an anatomical and molecular pathologist, address frequently asked questions about the importance of biomarker testing in NSCLC.

Released: August 31, 2022

Expiration: August 30, 2023

No longer available for credit.

Share

Faculty

Matthew Gubens

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Alexander Craig Mackinnon, Jr.

Alexander Craig Mackinnon, Jr., MD, PhD, MSHA

Robert B. Adams Endowed Professor
Professor and Director, Division of Genomic Diagnostics & Bioinformatics
Department of Pathology
The University of Alabama at Birmingham Heersink School of Medicine
Birmingham, Alabama

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bayer Healthcare Pharma

Daiichi Sankyo, Inc.

Genentech TEXT Only

Janssen administered by Scientific Affairs

Lilly

Novartis Pharmaceuticals Corporation

Partners

AMP

ProCE Banner

Faculty Disclosure

Primary Author

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Matthew Gubens, MD, MS: consultant/advisor/speaker: AstraZeneca, Bristol-Myers Squibb, Cardinal Health, Genentech/Roche, Genzyme/Sanofi, Guardant, iTeos, Surface; researcher (paid to institution): Amgen, Celgene, Johnson & Johnson, Merck, Novartis, OncoMed, Trizell.

Alexander Craig Mackinnon, Jr., MD, PhD, MSHA

Robert B. Adams Endowed Professor
Professor and Director, Division of Genomic Diagnostics & Bioinformatics
Department of Pathology
The University of Alabama at Birmingham Heersink School of Medicine
Birmingham, Alabama

Craig Mackinnon, MD, PhD, has no relevant financial relationships to disclose.